Related Experiment Video
Updated: Oct 2, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors
Ana Luiza Gomes de Morais1, Sara Cerdá2, Maria de Miguel3
1START Madrid-Fundación Jiménez Díaz (FJD) Early Phase Program, Fundación Jiménez Díaz Hospital, Madrid, Spain.
Purpose Of Review:
Even though checkpoint inhibitors have become a recent milestone for the treatment of many different tumor types, eventually, most part of patients will develop resistance mechanisms and their disease will progress. New generations of checkpoint inhibitors, as the ones directed to TIM-3, are on research.
Recent Findings:
TIM-3 expression has been associated with more advanced stages and shorter survival in several tumor types, due to its association with T-cell dysfunction, and has become an interesting target to explore. Early phase clinical trials with different anti-TIM-3 monoclonal antibodies have shown a safe toxicity profile, as cobolimab, LY3321367, or sabatolimab; however, the general antitumor activity remains to be determined and further investigations are needed. TIM-3 is implicated in resistance to immunotherapy due to its role in T cell exhaustion. However, the TIM-3 pathway is highly complex in terms of non-canonical signaling, broad expression by different immune cells and multiple ligands. Different anti-TIM-3 inhibitors are currently on research, either as monotherapy or in combination with other immunotherapies or chemotherapy, aiming to overcome resistance.
Insights
New checkpoint inhibitors targeting TIM-3 (T-cell immunoglobulin and mucin-domain containing-3) show promise for overcoming immunotherapy resistance. Further research is needed to determine their overall antitumor activity and optimal use in cancer treatment.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Immune checkpoint inhibitors (ICIs) are a significant advancement in cancer therapy, but acquired resistance limits their long-term efficacy.
- T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) is increasingly recognized as a key mediator of T-cell dysfunction and a mechanism of resistance to ICIs.
Purpose of the Study:
- To review the role of TIM-3 in cancer immunotherapy resistance.
- To discuss emerging anti-TIM-3 therapies and their potential to overcome treatment limitations.
Main Methods:
- Review of preclinical and clinical data on TIM-3 expression and function in cancer.
- Analysis of early-phase clinical trials investigating anti-TIM-3 monoclonal antibodies.
Main Results:
- TIM-3 expression correlates with advanced disease stages and poorer survival across various cancer types.
- Early clinical trials of anti-TIM-3 antibodies (e.g., cobolimab, LY3321367, sabatolimab) demonstrate a favorable safety profile.
- The precise antitumor efficacy of anti-TIM-3 agents requires further clinical validation.
Conclusions:
- TIM-3 represents a promising therapeutic target for enhancing anti-tumor immunity and overcoming resistance to current immunotherapies.
- Further investigation into combination strategies involving anti-TIM-3 agents with other treatments is warranted to improve patient outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...